Advances in anticoagulation: Focus on dabigatran, an oral direct thrombin inhibitor

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 25, Issue 6, 2011, Pages 1208-1212

  Augoustides, John G T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

anticoagulation; atrial fibrillation; dabigatran; glycoprotein transporter; hemodialysis; hip arthroplasty; knee arthroplasty; mechanical heart valve; renal dysfunction; reversal agent; thrombin; venous thromboembolism

Indexed keywords

AMIODARONE; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; FRESH FROZEN PLASMA; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN COMPLEX; QUINIDINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIFAMPICIN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD COMPONENT THERAPY; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HIP ARTHROPLASTY; HUMAN; INTESTINE ABSORPTION; KIDNEY DYSFUNCTION; KNEE ARTHROPLASTY; LIVER TOXICITY; LUNG EMBOLISM; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL ANESTHESIA; REVIEW; STROKE; THROMBIN TIME; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANESTHESIA, CONDUCTION; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CHEMISTRY, PHARMACEUTICAL; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBIN; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 82255192497     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2011.08.005     Document Type: Review

References (35)

1. J.W. Eikelboom, and J.I. Weitz New anticoagulants Circulation 121 2010 1523 1532
2. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
3. R. Nieuwlaat, A. Capucci, and A.J. Camm Atrial fibrillation management: A prospective survey of ESC member countries: The Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434
4. E. Birman-deych, M.J. Radford, and D.S. Nilasena Use and effectiveness of warfarin in Medicare beneficiaries with trial fibrillation Stroke 37 2006 1070 1074
5. L. Testa, R. Bhindi, and P. Agostoni The direct thrombin inhibitor ximelagatran/melagatran: A systematic review on clinical applications and an evidence-based assessment of risk benefit profile Expert Opin Drug Saf 6 2007 397 406
6. S. Tujios, and R.J. Fontana Mechanisms of drug-induced liver injury: From bedside to bench Nat Rev Gastroenterol Hepatol 8 2011 202 211
7. J. Stangier, H. Stable, and K. Rathgen Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 2008 47 59
8. W.G. Eisert, N. Hauel, and J. Stangier Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin Arterioscler Thromb Vasc Biol 30 2010 1885 1889
9. J.I. Weitz, B. Leslie, and M. Hudoba Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors Circulation 97 1998 544 552
10. T. Ebner, K. Wagner, and W. Wienen Dabigatran acylglucoronide: The major human metabolite of dabigatran: In vitro formation, stability and pharmacological activity Drug Metab Dispos 38 2010 1567 1575
11. J. Stangier, K. Rathgen, and H. Sthle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etelixate: An open label, parallel group, single-centre study Clin Pharmacokinet 49 2010 259 268
12. G.J. Hankey, and J.W. Eikelboom Dabigatran etexilate: A new oral thrombin inhibitor Circulation 123 2011 1436 1450
13. J. Van Ryn, J. Standier, and K. Liesenfeld Dabigatran etexilate: A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
14. O. Sergent, K. Ekroos, and L. Lefeuvre-Orfila Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes Toxicol In Vitro 23 2009 1305 1310
15. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate versus subcutaneous enozaprin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
16. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigtran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomized, double-blind, non-inferiority trial Lancet 370 2007 1949 1956
17. J.S. Ginsberg, B.L. Davidson, and P.C. Comp Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
18. B.I. Eriksson, O.E. Dahl, and M.H. Huo Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomized, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
19. B.I. Eriksson, D.J. Quinlan, and J.W. Eikelboom Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 62 2011 41 57
20. S. Schulman, C. Kearon, and A.K. Kakkar Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
21. M.D. Ezekowitz, S. Connolly, and A. Parekh Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulation therapy, warfarin, compared with dabigatran Am Heart J 157 2009 805 810
22. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
23. L. Wallentin, S. Yusf, and M.D. Ezekowitz Efficacy and safety of dabigatran with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: An analysis of the RELY trial Lancet 376 2010 975 983
24. J.V. Freeman, R.P. Zhu, and D.K. Owens Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
25. S.V. Shah, and B.F. Gage Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation Circualtion 123 2011 2562 2570
26. S.V. Sorensen, A.R. Kansai, and S. Connolly Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective Thromb Haemaost 105 2011 908 919
27. L.S. Wann, A.B. Curtis, and K.A. Ellenbogen ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 57 2011 1330 1337
28. U. Baber, S. van der Zee, and V. Fuster Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation Curr Cardiol Rep 12 2010 133 139
29. L. Maegdefessel, T. Linde, and F. Krapiec In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves Thromb Res 126 2010 196 200
30. S.H. McKellar, S. Abel, and C.L. Camp Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves J Thorac Cardiovasc Surg 141 2011 1410 1416
31. J. van Ryn, T. Litzenburger, and A. Waterman Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models J Am Coll Cardiol 57 2011 E1130
32. J. Stangier, and A. Clemens Pharmacology, pharmacokinetics and pharmacodynamics of dabigatran etexilate: An oral direct thrombin inhibitor Clin Appl Thromb Hemost 15 2009 9S 16S
33. E. Romualdi, E. Rancan, S. Siragusa E. Rancan, and S. Siraqusa Managing bleeding complications in patients treated with the old and new anticoagulants Curr Pharm Des 16 2010 3478 3482
34. T.T. Horlocker, D.J. Wedel, and J.C. Rowlingson Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-based Guidelines (third edition) Reg Anesth Pain Med 35 2010 64 101
35. W. Gogarten, E. vandermeulen, and H. Van Aken Regional anesthesia and antithrombotic agents: Recommendation of the European Society of Anesthesiology Eur J Anaesthesiol 27 2010 999 1015